CEACAM5 and neoplasm: CEACAM5 is markedly overexpressed (≥50% of tumour cells) in epithelial-derived carcinomas, with the highest prevalence in gastrointestinal malignancies (70–90% of colorectal, 50–70% of gastric, and 40–60% of pancreatic cancers) [31].